Bridge Laboratories reported the FDA accepted data submitted from its Beijing animal lab for an unnamed US biotech client. In its Beijing facility, Bridge conducted nonhuman primate toxicology tests, and the resulting data was submitted to the FDA as part of an IND package. Bridge said that the submission validates its business plan: a fully GLP compliant facility in Beijing that can conduct GLP studies in support of worldwide regulatory submissions at a lower cost than labs in the West. More details...